National Adult Tobacco Survey 2012-2013, 2013-2014
Principal Investigator: Sean Hu / Hannah Day
Funding Mechanism: Interagency Agreement
ID number: 224-10-9022
Award Date: 1/1/2011
Institution: Centers for Disease Control and Prevention
The National Adult Tobacco Survey (NATS) -- a nationally-representative cross-sectional random-digit-dialed annual telephone survey of U.S. adults aged 18 and older -- seeks to determine tobacco use prevalence and the factors promoting and impeding tobacco use. Questionnaire items measure cigarette use (including menthol and roll-your-own cigarette use); young adult susceptibility to use of cigarettes; cigarette purchasing behaviors; use of cigars and physical properties of cigars used; use of smokeless tobacco, snus, dissolvable tobacco, pipes, waterpipes, and electronic cigarettes; susceptibility to use of non-cigarette tobacco products; use of flavored non-cigarette tobacco products; and measures of addiction, cessation, tobacco marketing exposure, and knowledge, attitudes, and beliefs regarding tobacco use. In 2012-2013, the overall response rate for the survey was 44.9% with a sample size of 60,064 adults; the target sample size for 2013-2014 is 75,000 adults. Study aims are: (1) to estimate the national burden of tobacco use among adults, including the use of new and emerging products and dual/poly tobacco use, and assess the degree to which tobacco use behaviors vary as a function of gender, age, race/ethnicity, socioeconomic status, and sexual orientation; (2) to assess trends in product preferences, such as menthol and flavored product use, and examine potential associated differences in frequency of product use, dependence, cessation and risk perceptions; (3) to monitor susceptibility to tobacco product use and consumer perceptions regarding tobacco products, and monitor whether perceptions change over time; and (4) to monitor population-level exposure to tobacco health warnings and determine levels of exposure to prohibited marketing. This survey may yield nationally representative data to inform FDA regulatory activities and may generate hypotheses regarding underlying mechanisms that may inform future research.